Veracyte specializes in advanced cancer diagnostics, focusing on molecular tests that provide critical insights for clinicians in the diagnosis and treatment of various cancers. Their portfolio includes tests such as the Afirma® Genomic Sequencing Classifier for thyroid cancer, the Decipher® Prostate Genomic Classifier for prostate cancer, and the Prosigna® Breast Cancer Assay for breast cancer. These tests are designed to help clinicians make informed decisions at pivotal moments in a patient's cancer care journey, reducing uncertainty and potentially avoiding unnecessary procedures. Veracyte's approach emphasizes collaboration with healthcare professionals to identify unmet clinical needs, leading to the development of high-performance tests that are supported by robust clinical evidence and reimbursement strategies.

In addition to their existing tests, Veracyte is actively expanding its offerings through the development of new in vitro diagnostic (IVD) tests and enhancements to current tests. Their innovative MRD (minimal residual disease) assay utilizes whole-genome sequencing combined with artificial intelligence to monitor cancer more effectively, requiring less blood and providing faster results. This technology aims to improve patient outcomes by enabling earlier detection of residual disease and tracking tumor progression over time. Veracyte's commitment to making their diagnostics widely accessible is evident in their efforts to create IVD versions of their tests for global markets, ensuring that patients around the world can benefit from their cutting-edge cancer care solutions.

United States

Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. 

Our growing menu of diagnostic tests answers important clinical questions to help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment.

Veracyte

Company Details